A5017474339- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Angiogenesis and VEGF in Cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Research Studies
- RNA modifications and cancer
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Thyroid Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways
- HER2/EGFR in Cancer Research
- Cancer Research and Treatments
- Occupational and environmental lung diseases
- Cancer Immunotherapy and Biomarkers
- Medical Imaging and Pathology Studies
- Cancer-related molecular mechanisms research
- Cancer, Lipids, and Metabolism
- Cholangiocarcinoma and Gallbladder Cancer Studies
- MicroRNA in disease regulation
- Pleural and Pulmonary Diseases
- Melanoma and MAPK Pathways
- Cancer Mechanisms and Therapy
University of Pisa
2016-2025
Azienda Ospedaliera Universitaria Pisana
2013-2024
University Health Network
2017
Massachusetts General Hospital
2017
Università Cattolica del Sacro Cuore
2017
Virginia Commonwealth University
2017
John Wiley & Sons (United States)
2017
Hudson Institute
2017
Fondazione IRCCS Istituto Nazionale dei Tumori
2016
Ospedale di Livorno
1996-2014
Agents targeting programmed death-1 receptor (PD-1) and its ligand (PD-L1) are showing promising results in non-small-cell lung cancer (NSCLC). It is unknown whether PD-1/PD-L1 differently expressed oncogene-addicted NSCLC. We analysed a cohort of 125 NSCLC patients, including 56 EGFR mutated, 29 KRAS 10 ALK translocated 30 EGFR/KRAS/ALK wild type. PD-L1 PD-1 expression were assessed by immunohistochemistry. All cases with moderate or strong staining (2+/3+) >5% tumour cells considered as...
KRAS codons 12 and 13 mutations predict resistance to anti-EGFR monoclonal antibodies (moAbs) in metastatic colorectal cancer. Also, BRAF V600E mutation has been associated with resistance. Additional are described CRC. We investigated the role of 61 146 predicting cetuximab plus irinotecan a cohort wild-type patients. Among 87 patients, were mutated 7 1 case, respectively. None patients responded vs 22 68 wild type (P=0.096). Eleven not evaluable. shorter progression-free survival (PFS, HR:...
Next-generation sequencing (NGS) was applied to 148 lung neuroendocrine tumours (LNETs) comprising the four World Health Organization classification categories: 53 typical carcinoid (TCs), 35 atypical (ACs), 27 large-cell carcinomas, and 33 small-cell carcinomas. A discovery screen conducted on 46 samples by use of whole-exome high-coverage targeted 418 genes. Eighty-eight recurrently mutated genes from both current literature were verified in cases screen, validated additional 102 LNETs...
MET-deregulated NSCLC represents an urgent clinical need because of unfavorable prognosis and lack specific therapies. Although recent studies have suggested a potential role for crizotinib in patients harboring MET amplification or exon 14 mutations, no conclusive data are currently available. This study aimed at investigating activity ROS1 alterations.Patients with pretreated advanced evidence rearrangements (cohort A) deregulation (amplification, ratio MET/CEP7 >2.2 cohort B) were treated...
Tumors acquire nutrients that are essential for continued growth and an avenue dissemination to the rest of body by inducing angiogenesis (i.e., formation new blood vessels). Preliminary studies involving a number different kinds cancer have indicated assessment tumor may be useful in predicting disease outcome.In prospective study, we evaluated relationship between survival 407 patients with non-small-cell lung carcinoma who were treated potentially curative surgery.The study population...
Abstract The growth of newly formed vessels, or neoangiogenesis, represents an important step in both physiological and pathological situations: particular, tumour metastasis require angiogenesis. Microvessel count (MC), which a measure angiogenesis, has been associated with metastatic spread cutaneous, mammary, prostatic, head neck, early‐stage lung cancer. In this study, the role angiogenesis as prognostic indicator was examined 253 primary non‐small cell cancer (NSCLC) patients....
Despite major advances in the management of metastatic colorectal cancer (mCRC) with liver-only involvement, relapse rates are high and reliable prognostic markers needed. To assess impact BRAF RAS mutations a large series liver-resected patients, medical records 3024 mCRC patients were reviewed. Eligible cases undergoing potentially curative liver resection selected. mutational status was tested on primary and/or metastases by means pyrosequencing mass spectrometry genotyping assay. Primary...
NRAS mutations occur in 3–5% of colorectal cancer. Differently from KRAS and BRAF mutations, the role as prognostic predictive markers metastatic cancer (mCRC) has been investigated to a lesser extent. A retrospective series suggested predictors resistance anti-EGFR monoclonal antibodies (MoAbs) chemo-refractory patients with mCRC. In our study, codons 12, 13, 61 codon 600 mutational status were evaluated mCRCs referred Institution 2009 2012. 13 was analyzed KRAS/BRAF wt patients. We...